Sugi Predict

Sugi Predict / Targets / CYP8B1

CYP8B1

7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase · Q9UNU6 · CYP8B1 on Sugi Atlas →

8,666 patent compounds predicted against CYP8B1, 6,708 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1966870 SCHEMBL1966870 0.38 16/20
SCHEMBL1966871 SCHEMBL1966871 0.38 16/20
SCHEMBL1968033 SCHEMBL1968033 0.38 16/20
SCHEMBL1968035 SCHEMBL1968035 0.38 16/20
SCHEMBL1966937 SCHEMBL1966937 0.36 16/20
SCHEMBL1966939 SCHEMBL1966939 0.36 16/20
SCHEMBL1968267 SCHEMBL1968267 0.36 16/20
SCHEMBL1969410 SCHEMBL1969410 0.36 14/20
SCHEMBL1969413 SCHEMBL1969413 0.36 14/20
SCHEMBL1968176 SCHEMBL1968176 0.34 14/20
SCHEMBL1968179 SCHEMBL1968179 0.34 14/20
SCHEMBL1968208 SCHEMBL1968208 0.34 14/20
SCHEMBL1967640 SCHEMBL1967640 0.33 13/20
SCHEMBL1967803 SCHEMBL1967803 0.33 13/20
SCHEMBL1967805 SCHEMBL1967805 0.33 13/20
SCHEMBL1967549 SCHEMBL1967549 0.38 12/20
SCHEMBL1967551 SCHEMBL1967551 0.38 12/20
SCHEMBL1965915 SCHEMBL1965915 0.37 12/20
SCHEMBL1969514 SCHEMBL1969514 0.36 12/20
SCHEMBL1967120 SCHEMBL1967120 0.36 12/20

Clinical trials — most relevant to CYP8B1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity PHASE4COMPLETED
Phase III Study on HMPL-523 for Treatment of ITP PHASE3COMPLETED
Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis PHASE2COMPLETED
3 Month PHI PAD PoM Study PHASE2COMPLETED
Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis PHASE2RECRUITING
Oral Cannabidiol for Opioid Withdrawal PHASE1/PHASE2COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma PHASE2NOT_YET_RECRUITING
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities PHASE2UNKNOWN
A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors PHASE1/PHASE2RECRUITING
Androgen Reduction in Congenital Adrenal Hyperplasia PHASE2WITHDRAWN
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
A Study of GLB-001 in Patients With Myeloid Malignancies PHASE1RECRUITING
The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause PHASE1COMPLETED
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria PHASE1RECRUITING
Comparison of Efficacy of Single Oral Dose Fluconazole and Itraconazole in Patients With Pityriasis Versicolor PHASE1COMPLETED
Phase 1 Study of ATRS-2002 in Healthy Male Adults PHASE1WITHDRAWN
A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function PHASE1COMPLETED
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies PHASE1UNKNOWN
Identification of New Tools for Predicting Natural Metabolic Performance of the Liver PHASE1RECRUITING
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole nanWITHDRAWN
Involvement of Pollutants in Atopic Dermatitis and Psoriasis nanUNKNOWN
Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum nanCOMPLETED
Mutation Analysis of 17α-Hydroxylase nanUNKNOWN
Study of Smith-Lemli-Opitz Syndrome nanCOMPLETED
Cholesterol Metabolites as Markers for CYP3A Induction nanCOMPLETED
Connecting Breath and Mind for CYP With Long COVID nanUNKNOWN
Effects of Colesevelam HCl On Bile Acid Kinetics nanCOMPLETED
Urinary PGE-MUM (PROSTAGLANDIN E-MAJOR URINARY METABOLITE) as Inflammatory Marker in Chronic Inflammatory Bowel Disease nanCOMPLETED
Molecular Epidemiology of Dioxin-Related Illness in Seveso nanCOMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP8B1 binder may also engage these)

ProteinNameSimilarity
O88962 — 1.000 O88962 →
Q7YRB2 — 0.998 Q7YRB2 →
O02766 — 0.996 O02766 →
F1RE08 — 0.995 F1RE08 →
Q60991 — 0.992 Q60991 →
Q62969 — 0.987 Q62969 →
CYP7B1 Cytochrome P450 7B1 0.986 landscape →
G3V7X8 — 0.984 G3V7X8 →
Q63688 — 0.983 Q63688 →
O46491 — 0.982 O46491 →
O35074 — 0.982 O35074 →
Q64505 — 0.981 Q64505 →
Q28827 — 0.981 Q28827 →
Q811W2 — 0.980 Q811W2 →
E1BHJ4 — 0.979 E1BHJ4 →
P00189 — 0.978 P00189 →
Q9JKJ9 — 0.978 Q9JKJ9 →
P97720 — 0.977 P97720 →
O35084 — 0.977 O35084 →
P0DOX0 — 0.977 P0DOX0 →
P51542 — 0.976 P51542 →
Q9DBG1 — 0.976 Q9DBG1 →
P79153 — 0.976 P79153 →
Q29626 — 0.975 Q29626 →
Q9QZ82 — 0.974 Q9QZ82 →
PTGIS Prostacyclin synthase 0.974 landscape →
P18125 — 0.973 P18125 →
P17178 — 0.973 P17178 →
CYP21A2 Steroid 21-hydroxylase 0.972 landscape →
P14137 — 0.972 P14137 →